T-cell clones from melanoma patients immunized against an anchor- modified gp100 peptide display discordant effector phenotypes

Cancer Journal

Volumn 6, Issue 2, 2000, Pages 69-77

  Dudley, Mark E ^a   Ngo, Lien T ^a   Westwood, Jennifer ^a   Wunderlich, John R ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cytotoxic T lymphocyte; Epitopes therapeutic use; Immunotherapy adoptive; Melanoma

Indexed keywords

GLYCOPROTEIN GP 100;

ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOLOGY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MELANOCYTE; MELANOMA; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE;

CD8-POSITIVE T-LYMPHOCYTES; CLONE CELLS; FREUND'S ADJUVANT; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HLA-A2 ANTIGEN; HUMANS; IMMUNIZATION; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; INTERLEUKIN-2; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033941834     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Rosenberg SA, Yang JC, White DE et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998;228:307-319.
2. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989;142:3714-3725.
3. Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159-1166.
4. Kawakami Y, Rosenberg SA. Human tumor antigens recognized by T-cells. Immunol Res 1997;16:313-339.
5. Rosenberg SA. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst 1996;88:1635-1644.
6. Tsai V, Southwood S, Sidney J et al. Identification of subdominant CTL epitopes of the GP1000 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol 1997;158:1796-1802.
7. Bakker AB, Schreurs MW, Tafazzul G et al. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. Int J Cancer 1995;62:97-102.
8. Kawakami Y, Eliyahu S, Jennings C et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphoqtes associated with in vivo tumor regression. J Immunol 1995;154:3961-3968.
9. Kawakami Y, Robbins PF, Wang X et al. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol 1998;161:6985-6992.
10. Salgaller ML, Afshar A, Marincola FM et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 1995;55:4972-4979.
11. Parkhurst MR, Salgaller ML, Southwood S et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A0201-binding residues. J Immunol 1996;157:2539-2548.
12. Pass HA, Schwarz SL, Wunderlich JR et al. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am 1998;4:316-323.
13. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-327.
14. Dudley ME, Nishimura MI, Holt AKC et al. Anti-tumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. J Immunother 1999; 22:288-298
15. Salter RD, Cresswell P. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J 1986;5:943-949.
16. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989;142:3714-3725.
17. Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 1990;128:189-201.
18. Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-1044.
19. Irvine KR, Rao JB, Rosenberg SA et al. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 1996;156:238-245.
20. Barth RJ Jr, Mule JJ, Spiess PJ et al. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 1991;173:647-658.
21. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci U S A 1996;93:4102-4107.
22. Cerwenka A, Morgan TM, Harmsen AG et al. Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection. J Exp Med 1999;189:423-434.
23. Schwartzentruber DJ, Hom SS, Dadmarz R et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol 1994;12:1475-1483.
24. Pockaj BA, Sherry RM, Wei JP et al. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy: augmentation with cyclophosphamide and correlation with response. Cancer 1994;73:1731-1737.
25. Aebersold P, Hyatt C, Johnson S et al. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J Nad Cancer Inst 1991;83:932-937.